✦ LIBER ✦

A comparison of bortezomib, cyclophosphamide, and dexamethasone (Vel-CD) chemotherapy without and with thalidomide (Vel-CTD) for the treatment of relapsed or refractory multiple myeloma

✍ Scribed by Ahn, Jae-Sook; Yang, Deok-Hwan; Jung, Sung-Hoon; Park, Hyung Chul; Moon, Joon Ho; Sohn, Sang Kyun; Bae, Soo-Young; Kim, Yeo-Kyeoung; Kim, Hyeoung-Joon; Lee, Je-Jung

Book ID: 113027944
Publisher: Springer
Year: 2012
Tongue: English
Weight: 224 KB
Volume: 91
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s00277-012-1420-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical efficacy of a bortezomib, cyclo

Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study

✍ Yeo-Kyeoung Kim; Sang-Kyun Sohn; Jae-Hoon Lee; Deok-Hwan Yang; Joon-Ho Moon; Jae 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 175 KB

Bortezomib, doxorubicin, and dexamethaso

Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety

✍ Sung Sook Lee; Cheolwon Suh; Bong-Seog Kim; Jooseop Chung; Young-Don Joo; Hun-Mo 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 151 KB

Treatment of patients with relapsed/refr

Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies

✍ Dimopoulos, M A; Kastritis, E; Christoulas, D; Migkou, M; Gavriatopoulou, M; Gko 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 473 KB

A phase I study of bortezomib in combina

A phase I study of bortezomib in combination with doxorubicin and intermediate-dose dexamethasone (iPAD therapy) for relapsed or refractory multiple myeloma

✍ Yasushi Takamatsu; Kazutaka Sunami; Hiroyuki Hata; Koji Nagafuji; Ilseung Choi; 📂 Article 📅 2010 🏛 Carden Jennings Publishing 🌐 English ⚖ 167 KB

The combination of intermediate doses of

The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio

✍ Terpos, E; Mihou, D; Szydlo, R; Tsimirika, K; Karkantaris, C; Politou, M; Voskar 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 230 KB